"I'm thrilled to announce that Natalie Carfora is returning to Immunovia. This recruitment is business-critical for us, as her role is essential for securing coverage and driving revenue growth. Natalie is an ideal leader for this position, bringing exceptional expertise, deep familiarity with Immunovia, and a proven track record of success," said Jeff Borcherding, CEO of Immunovia.

After previously leading market access for Immunovia, Carfora recently led market access at Lucid Diagnostics. Carfora secured the first positive medical policy decision from a commercial payer for the company’s EsoGuard^® Esophageal DNA Test, and successfully guided the reconsideration request submission for Medicare coverage. While at Lucid Diagnostics, Carfora also led billing and revenue cycle management.

“I'm excited to return to Immunovia at a time when there's real momentum building here. As the launch of the PancreaSure test approaches and the reimbursement process moves forward, my experiences will help us navigate with speed and purpose,” said Natalie Carfora, new VP Market Access and Reimbursement.

Natalie Carfora brings extensive experience in market access and sales in medical diagnostics, successfully engaging with commercial and governmental payors on coverage policy. Previously, at Scipher Medicine, Myriad Genetics, as well as at Immunovia, she led market access initiatives including clinical study design collaboration, payor pilot programs, and utilizing clinical utility studies to inform coverage policies. Natalie is a graduate of Boston University School of Management with a B.S. in Business Administration.